Exosens Shares Rise by +2.6% and Test a Key Technical Zone
Exosens climbs 2.67% in mid-afternoon trading on Monday, April 27, 2026, reaching 65.45 euros, amid the release of its first-quarter results. The detection and amplification technology specialist has now seen an increase of over 88% year-over-year, confirming a sustained momentum since its IPO.
A Session Driven by Quarterly Publication and Favorable Technical Positioning
Exosens shares are significantly up this Monday, the day the group publishes its first-quarter 2026 results. Priced at 65.45 euros, the stock is moving above its 20-day (63.79 euros) and 50-day (63.59 euros) moving averages, indicating a short-term bullish momentum resurgence. The RSI, at 49, remains in a neutral zone and does not signal any overbought condition, leaving room for technical progress before reaching the upper Bollinger band at 69.41 euros. In the meantime, the CAC 40 is up by 0.32% during the session, while the SBF 120 has advanced by 0.34%. Among comparable stocks listed in Paris, Safran is up 1.30% and Airbus shows a modest increase of 0.18%. The European sector environment remains generally supportive, although major defense groups in the United States ended the last session in the red: RTX Corporation down 2.81%, Lockheed Martin 3.08%, and General Dynamics 1.73%.
A Remarkable Annual Trajectory and Upcoming Financial Deadlines
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over the year, Exosens' performance has reached 88.35%, a journey that has significantly pushed the stock price above its 200-day moving average, set at 50 euros. Over three months, the increase amounts to 22.57%, illustrating a recent acceleration. The most relevant technical support threshold is at 57.50 euros, while the identified resistance at 72.90 euros is the next level to watch if the upward movement continues. Following today's quarterly results publication, the group's financial calendar remains busy. The general assembly is scheduled for Friday, May 22, 2026, followed by the half-year results on Tuesday, July 28, 2026, and the third-quarter results on Tuesday, October 27, 2026. These successive appointments will provide regular checkpoints on Exosens' ability to sustain the growth trajectory supporting its valuation over the past year.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.